A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Latest Information Update: 04 Jan 2016
Price :
$35 *
At a glance
- Drugs Vandetanib (Primary) ; Capecitabine; Gemcitabine
- Indications Biliary cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 30 Dec 2015 Results published in the Investigational New Drugs
- 24 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.